17124594

Source:http://linkedlifedata.com/resource/pubmed/id/17124594

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0007102, umls-concept:C0016360, umls-concept:C1452684, umls-concept:C1512474, umls-concept:C1515655, umls-concept:C1516170, umls-concept:C1533691
pubmed:issue	2
pubmed:dateCreated	2007-5-11
pubmed:abstractText	Histone deacetylase inhibitors (HDACi) inhibit the growth of cancer cells, and combinations of HDACi with established chemotherapeutics can lead to synergistic effects. We have investigated effects of PXD101 (HDACi in phase II clinical trials) in combination with 5-fluorouracil, on tumour cell proliferation and apoptosis both in vitro and in vivo.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7806519
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations, http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/Histone Deacetylase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Hydroxamic Acids, http://linkedlifedata.com/resource/pubmed/chemical/PXD101
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	0344-5704
pubmed:author	pubmed-author:ChristiansenSanne JSJ, pubmed-author:CollinsLaura SLS, pubmed-author:DejligbjergMarielleM, pubmed-author:JensenPeter BuhlPB, pubmed-author:PetersenKamille DumongKD, pubmed-author:RitchieJames W AJW, pubmed-author:SehestedMaxwellM, pubmed-author:ThougaardAnnemetteA, pubmed-author:TumberAnthonyA
pubmed:issnType	Print
pubmed:volume	60
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	275-83
pubmed:dateRevised	2009-11-19
pubmed:meshHeading	pubmed-meshheading:17124594-Animals, pubmed-meshheading:17124594-Apoptosis, pubmed-meshheading:17124594-Cell Line, Tumor, pubmed-meshheading:17124594-Cell Proliferation, pubmed-meshheading:17124594-Colorectal Neoplasms, pubmed-meshheading:17124594-Dose-Response Relationship, Drug, pubmed-meshheading:17124594-Drug Combinations, pubmed-meshheading:17124594-Drug Synergism, pubmed-meshheading:17124594-Enzyme Inhibitors, pubmed-meshheading:17124594-Female, pubmed-meshheading:17124594-Fluorouracil, pubmed-meshheading:17124594-Histone Deacetylase Inhibitors, pubmed-meshheading:17124594-Humans, pubmed-meshheading:17124594-Hydroxamic Acids, pubmed-meshheading:17124594-Mice, pubmed-meshheading:17124594-Neoplasms, Experimental, pubmed-meshheading:17124594-Tumor Stem Cell Assay, pubmed-meshheading:17124594-Xenograft Model Antitumor Assays
pubmed:year	2007
pubmed:articleTitle	The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
pubmed:affiliation	TopoTarget UK LTD, 87a Milton Park, Abingdon, OXON, OX14 4RY, UK.
pubmed:publicationType	Journal Article